Ⅲ章 資料
胃癌治療を理解・実践する上で有用と思われる文献を英文論文を中心に集め,各分野ごとに出版年順にリストした(1)2)…)。ガイドライン本文の記述と直接関係するものは,本文中に文献番号([1][2]…)を記した。
1) | Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-14. |
---|---|
2) | Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-30. |
3) | Lekakos LN, Triantafillopoulos JK, Milingos ND, et al: Adenocarcinoma of the gastric cardia: treatment via a left thoracoabdominal approach. Am Surg 2002; 68: 584-90. |
4) | Wu CW, Hsiung CA, Lo SS, et al: Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-87. |
5) | Degiuli M, Sasako M, Calgaro M, et al: Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian gastric cancer study group(IGCSG)randomised surgical trial. EJSO 2004; 30: 303-8. |
6) | Hartgrink HH, van de Velde CJ, Putter H, et al: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-77. |
7) | Sano T, Sasako M, Yamamoto S, et al: Gastric cancer Surgery: Morbidity and mortality results from a prospective randomized controlled trial compariwng D2 and extended para-aortic lymphadenectomy―Japan clinical oncology group study 9501. J Clin Oncol 2004; 22: 2767-73. |
8) | Kodera Y, Sasako M, Yamamoto S, et al: Identification of risk factors for the development of complications following extended and surperextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92: 1103-09. |
9) | Sasako M, Sano T, Yamamoto S, et al: Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-51. |
10) | Kunisaki C, Akiyama H, Nomura M, et al: Comparison of surgical results of D2 versus D3 gastrectomy (Para-aortic lymph node dissection)for advanced gastric carcinoma: A multi-institutional study. Ann Surg Oncol 2006; 13: 659-67. |
11) | Marrelli D, Pedrazzani C, Neri A, et al: Complications after extended(D2)and superextended(D3)lymphadenectomy for gastric cancer: Analysis of potential risk factors. Ann Surg Oncol 2007; 14: 25-33. |
12) | Danielson H, Kokkola A, Kiviluoto T, et al: Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer. Scand J Surg 2007; 96: 35-40. |
13) | Yonemura Y, Wu CC, Fukushima N, et al: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008; 13: 132-37. |
14) | Sasako M, Sano T, Yamamoto S, et al: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Eng J Med 2008; 359: 453-62. |
15) | Peyre CG, Hagen JA, DeMeester SR, et al: The number of lymph nodes removed predicts survival in esophageal cancer: An international study on the impact of extent of surgical resection. Ann Surg 2008;248: 549-56. |
16) | Yang SH, Zhang YC, Yang KH, et al: An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg 2009; 197: 246-51. |
17) |
Tokunaga M, Ohyama S, Hiki N, et al: Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol 2009; 16: 1241-46. |
18) | Maehara Y, Moriguchi S, Yoshida M, et al: Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 1991; 67: 3006-9. |
---|---|
19) | Maruyama K, Sasako M, Kinoshita T, et al: Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 19: 532-6. |
20) | Bonenkamp JJ, Songun I, Hermans J, et al: Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in Dutch patients. Lancet 1995; 345(8952): 745-8. |
21) | Otsuji E, Yamaguchi T, Sawai K, et al: Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer 1999; 79: 1789-93. |
22) | Furukawa H, Hiratsuka M, Ishikawa O, et al: Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Ann Surg Oncol 2000; 7: 669-73. |
23) | Adachi Y, Kitano S, Sugimachi K: Surgery for gastric cancer: 10-year experience worldwide. Gastric Cancer 2001; 4: 166-74. |
24) | Sano T, Yamamoto S, Sasako M: Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002; 32: 363-4. |
25) | Csendes A, Burdiles P, Rojas J, et al: A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131: 401-7. |
26) | Yu W, Choi GS, Chung HY: Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93: 559-63. |
27) | Seto Y, Ishida T, Nagawa H, et al: Vascular invasion of early gastric cancer at resection line. Int Surg 2000; 85: 216-8. |
---|---|
28) | Sawai K, Takahashi T, Fujioka T, et al: Pylorus-preserving gastrectomy with radical lymph node dissection based on anatomical variations of the infrapyloric artery. Am J Surg 1995; 170: 285-8. |
29) | Zhang D, Shimoyama S, Kaminishi M: Feasibility of pylorus-preserving gastrectomy with a wider scope of lymphadenectomy. Arch Surg 1998; 133: 993-7. |
30) | Hinoshita E, Takahashi I, Onohara T, et al: The nutritional advantages of proximal gastrectomy for early gastric cancer. Hepatogastroenterol 2001; 48: 1513-6. |
31) | Nakabayashi T, Mochiki E, Garcia M, et al: Pyloric motility after pylorus-preserving gastrectomy with or without the pyloric branch of the vagus nerve. World J Surg 2002; 26: 577-83. |
32) | Yokota T, Ishiyama S, Saito T, et al: Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 2003; 4: 423-8. |
33) | Katai H, Sano T, Fukagawa T, et al: Prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach. Br J Surg 2003; 90: 850-3. |
34) | Shibata C, Shiiba KI, Funayama Y, et al: Outcomes after pylorus-preserving gastrectomy for early gastric cancer: a prospective multicenter trial. World J Surg 2004; 28: 857-61. |
35) | Kitagawa Y, Kitano S, Kubota T, et al: Minimally invasive surgery for gastric cancer-toward a confluence of two major streams:a review. Gastric Cancer 2005; 8: 103-10. |
36) | Arigami T, Natsugoe S, Uenosono Y, et al: Evaluation of sentinel node concept in gastric cancer based lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg 2006; 243: 341-7. |
37) | Ohdaira H, Nimura H, Mitsumori N, et al: Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. Gastric Cancer 2007; 10: 117-22. |
38) | Park do J, Lee HJ, Jung HC, et al: Clinical outcome of pylorus-preserving gastrectomy in gastric cancer in comparison with conventional distal gastrectomy with Billroth I anastomosis. World J Surg 2008; 32: 1029-36. |
39) | Morita S, Katai H, Saka M, et al: Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Cancer 2008; 95: 1131-5. |
40) | Ishikawa S, Shimada S, Miyanari N, et al: Pattern of lymph node involvement in proximal gastric cancer. World J Surg 2009; 33: 1687-92. |
41) | Hiki N, Sano T, Fukunaga T, Ohyama S, et al: Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg 2009; 209: 297-301. |
42) | Ochiai T, Sasako M, Mizuno S, et al: Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 1994; 81: 1175-8. |
---|---|
43) | Furukawa H, Hiratsuka M, Iwanaga T, et al: Extended surgery―left upper abdominal exenteration plus Appleby’s method―for type 4 gastric carcinoma. Ann Surg Oncol 1997; 4: 209-14. |
44) | Yonemura Y, Kawamura T, Nojima N, et al: Postoperative results of left upper abdominal evisceration for advanced gastric cancer. Hepatogastroenterol 2000; 47: 571-4. |
45) | Ajisaka H, Fujita H, Kaji M, et al: Treatment of patients with gastric cancer and duodenal invation. Int Surg 2001; 86: 9-13. |
46) | Isozaki H, Tanaka N, Fujii K, et al: Improvement of the prognosis of gastric cancer with extensive serosal invasion using left upper abdominal evisceration. Hepatogastroenterol 2001; 48: 1179-82. |
47) | Nomura E, Niki M, Fujii K, et al: Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001; 4: 75-82. |
48) | Ambiru S, Miyazaki M, Ito H, et al: Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001; 181: 279-83. |
49) | Okano K, Maeba T, Ishimura K, et al: Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235: 86-91. |
50) | Shirabe K, Shimada M, Matsumata T, et al: Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterol 2003; 50: 1560-3. |
51) | Saka M, Mudan SS, Katai H, et al: Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer 2005; 8: 1-5. |
52) | Lee HJ, Park do J, Lee KU: Pancreaticoduodenectomy for locally advanced gastric cancer. Hepatogastroenterol 2007; 54: 977-80. |
53) | Sakamoto Y, Sano T, Shimada K, et al: Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534-9. |
54) | Nunobe S, Hiki N, Ohyama S, et al: Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. Langenbecks Arch Surg 2008; 393: 157-62. |
55) | Wang XB, Yang LT, Zhang ZW, et al: Pancreaticoduodenectomy for advanced gastric cancer with pancreaticoduodenal region involvement. World J Gastroenterol 2008; 14: 3425-9. |
56) | Tiberio GA, Coniglio A, Marchet A, et al: Metachronous hepatic metastases from gastric carcinoma: A multicentric survey. EJSO 2009; 35: 486-91. |
57) | Kaminishi M, Yamaguchi H, Shimizu N, et al: Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg 1997; 132: 184-7. |
---|---|
58) | Hartgrink HH, Putter H, Klein Kranenbarg E, et al: Value of palliative resection in gastric cancer. Br J Surg 2002; 89: 1438-43. |
59) | Lim S, Muhs BE, Marcus SG, et al: Results following resection for stage Ⅳ gastric cancer: are better outcomes observed in selected patient subgroups? J Surg Oncol 2007; 95: 118-22. |
60) | Sarela AI, Yelluri S: Gastric adenocarcinoma with distant metastasis. Arch Surg 2007; 142: 143-9. |
61)
|
Fujitani K, Yang HK, Kurokawa Y, et al: Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group study JCOG 0705 and Korea Gastric Cancer Association study KGCA01. Jpn J Clin Oncol 2008; 38: 504-6. |
62) | Saito H, Yamada Y, Tsujitani S, et al: Clinicopathologic characteristics of gastric cancer patients who underwent noncurative gastrectomy with long-term survival. Langenbecks Arch Surg 2009; 394: 99- 103. |
63) | Hioki M, Gotohda N, Konishi M, et al: Predictive factors improving survival after |
64) | Kitano S, Iso Y, Moriyama M, et al: Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994; 4: 146-8. |
---|---|
65) | Adachi Y, Suematsu T, Shiraishi N, et al: Quality of life after laparoscopy-assisted Billroth I gastrectomy. Ann Surg 1999; 229: 49-54. |
66) | Kitano S, Shiraishi N, Fujii K, et al: A randomized controlled trial comparing open vs laparoscopyassisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002; 131(1 Suppl): S306-11. |
67) | Huscher CG, Mingoli A, Sgarzini G, et al: Laparoscopic versus open subtotal gastrectomy for distal gastric cancer. Ann Surg 2005; 241: 232-7. |
68) | Lee JH, Han HS, Lee JH: A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer. Surg Endosc 2005; 19: 168-73. |
69) | Lee SI, Choi YS, Park DJ, et al: Comparative study of laparoscopy-assisted distal gastrectomy and open distal gastrectomy. J Am Coll Surg 2006; 202: 874-80. |
70) | Kitano S, Shiraishi N, Uyama I, et al: A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007; 245: 68-72. |
71) | Yasuda K, Shiraishi N, Etoh T, et al: Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 2007; 21: 2150-3. |
72) | Memon MA, Khan S, Yunus RM, et al: Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-9. |
73) | Fujiwara M, Kodera Y, Misawa K, et al: Long term outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. J Am Coll Surg 2008; 206: 138-43. |
74) | Lee JH, Yom CK, Han HS: Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc 2009; 23: 1759-63. |
75) | Cho GS, Kim W, Kim HH, et al: Multicentre study of the safety of laparoscopic subtotal gastrectomy for gastric cancer in the elderly. Br J Surg 2009; 96: 1437-42. |
76) | Lee SW, Nomura E, Bouras G, et al: Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg 2010; 211: 33-40. |
77) | 辻仲利政,黒川幸典,土岐祐一郎,他:cT2/3 胃癌手術における網嚢切除の意義に関するランダム化比較試験:中間解析結果.第81回日本胃癌学会総会,東京,2009. |
---|
78) | 長南明道,望月福治,池田卓,他:平坦・陥凹型早期胃癌の口側浸潤範囲の内視鏡診断能の検討.Gastroenterol Endosc 1992; 34: 775-83. |
---|---|
79) | 馬場保昌,吉田論史,長浜隆司,他:胃 X 線検査のポイント.精密検査法.胃と腸 2003; 38: 872-84. |
80)
|
Uedo N, Takeuchi Y, Yamada T, et al: Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol 2007; 102: 1610-6. |
81) | 八尾恒良,田邊寛,長浜孝,他:胃の陥凹型 SM 癌の病理組織構築と対比した内視鏡所見.胃と腸 2008; 43: 1109-25. |
82) | Yao K, Anagnostopoulos GK, Ragunath K: Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy 2009; 41: 462-8. |
83) | Ezoe Y, Muto M, Horimatsu T, et al: Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc 2010; 71: 477-84. |
84) | Gotoda T, Yanagisawa A, Sasako M, et al: Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers, Gastric Cancer 2000; 3: 219-25. |
---|---|
85) | Hanaoka N, Tanabe S, Mikami T, et al: Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection. Endoscopy 2009; 41: 427-32. |
86) | Hirasawa T, Gotoda T, Miyata S, et al: Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009; 12: 148-52. |
87) | Hirao M, Masuda K, Asanuma T, et al: Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 1988; 34: 264-9. |
---|---|
88) | Tada M, Murakami A, Karita M, et al: Endoscopic resection of early gastric cancer. Endoscopy 1993; 25: 445-50. |
89) | Inoue H, Takeshita K, Hori H, et al: Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993; 39: 58-62. |
90) | 小野裕之,後藤田卓志,近藤仁,他:IT ナイフを用いた EMR-適応拡大の工夫-.消化器内視鏡 1999; 11: 675. |
91) | Yamamoto H, Yube T, Isoda N, et al: A novel method of endoscopic mucosal resection using sodium hyaluronate. Gastrointest Endosc 1999; 50: 251-6. |
92) | Oyama T, Kikuchi Y: Aggressive endoscopic mucosal resection in the upper GI tract-hook knife EMR method. Minim Invasive Ther Allied Technol 2002; 11: 291-5. |
93) | Yahagi N, Fujishiro M, Kakushima N, et al: Endoscopic submucosal dissection for early gastric cancer using the tip of an electro-surgical snare(thin type). Dig Endosc 2004; 16: 34-8. |
94) | Inoue H, Sato Y, Kazawa T, et al: Endoscopic submucosal dissection-using a triangle-tipped knife[inJapanese]. Stomach Intestine 2004; 39: 53-6. |
95) | Fujishiro M, Yahagi N, Kashimura K, et al: Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy 2004; 36: 579-83. |
96) | Ono H, Hasuike N, Inui T, et al: Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008; 11: 47-52. |
97) | Ono H, Kondo H, Gotoda T, et al: Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225-9. |
---|---|
98) | Minami S, Gotoda T, Ono H, et al: Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery(with video). Gastrointest Endosc 2006; 63: 596-601. |
99) | Coda S, Oda I, Gotoda T, et al: Risk factors for cardiac and pyloric stenosis after endoscopic submucosal dissection, and efficacy of endoscopic balloon dilation treatment. Endoscopy 2009; 41: 421-6. |
100) | Takizawa K, Oda I, Gotoda T, et al: Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection±An analysis of risk factors. Endoscopy 2008; 40: 179-83. |
101) | Gossner L, Ell C: Photodynamic therapy of gastric cancer. Gastrointest Endosc Clin N Am 2000; 10: 461-80. |
102) | Sagawa T, Takayama T, Oku T, et al: Argon plasma coagulation for successful treatment of early gastric cancer with intramucosal invasion. Gut 2003; 52: 334-9. |
103) | 草野 央,後藤田卓志,岩崎 基,他:早期胃癌に対する内視鏡的切除後の長期予後.胃と腸 2008; 43: 74-80. |
104) | Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7. |
105) |
Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253: 2061-7. |
---|---|
106)
|
Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin―a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-31. |
107) | Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-8. |
108) | Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-FU, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. |
109) | Kim NK, Park YS, Heo DS, et al: A phase Ⅲ randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-8. |
110) | Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-90. |
111) | Cullinan SA, Moertel CG, Wieand HS, et al: Controlled evaluation of three drugs combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol 1994; 12: 412-6. |
112) |
Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX)plus supportive care with best supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995; 71: 587-91. |
113) | Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7. |
114) |
Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase Ⅲ trial of sequential highdose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000; 18: 2648-57. |
115) | Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase Ⅲ trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer: JCOG study 9205. J Clin Oncol 2003; 21: 54-9. |
116) | Cutsem EV, Moiseyenko VM, Tjulandin S, et al: Phase Ⅲ study of docetaxel with cisplatin and 5-fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24: 4991-7. |
117) | Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46. |
118) |
Koizumi W, Narahara H, Hara T, et al: Randomized phase Ⅲ study of S-1 alone versus S-1+cisplatin in the treatment for advanced gastric cancer(The SPIRITS trial)SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Lancet Oncol 2008; 9: 215-21. |
119) |
Imamura H, Iishi H, Tsuburaya A, et al: Randomized phase Ⅲ study of irinotecan plus S-1(IRIS)versus S-1 alone as first-line treatment for advanced gastric cancer(GC0301/TOP-002). 2008 Gastrointestinal Cancer Symposium. |
120) | Boku N, Yamamoto S, Shirao K, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase3 study. Lancet Oncol 2009; 10: 1063-9. |
121) |
Shirao K, Boku N, Yamada Y, et al: Randomized phase Ⅲ study of 5-fluorouracil continuous infusion(5- FUci)versus methotrexate and 5-FU sequentia(l MF)in gastric cancer with peritoneal metastasis: JCOG 0106. Proc Am Soci Clin Oncol 2009; 27: #4545. |
122) |
Cutsem EV, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: a phase Ⅲ study of trastuzumab added to standard chemotherapy(CT)in first-line human epidermal growth factor receptor 2(HER2) positive advanced gastric cancer(GC). Proc Am Soci Clin Oncol 2009; 27: #4509. |
123) |
Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/ infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 2010; 28: 1547-53. |
124) | Kang Y, Ohtsu A, Cutsem EV, et al: AVAGAST: A randomized, double-blind, placebo-controlled, phase Ⅲ study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. Proc Am Soci Clin Oncol 2010; 28: LBA4007. |
125) | Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-7. |
---|---|
126) | Furukawa H, Iwanaga T, Nakajima T, et al: Randomized study with mitomycin C+5-fluorouracil+cytosine arabinoside(MFC)+5-fluorouracil, MFC+tegafur and uraci(l UFT), and MF+UFT in advanced gastric cancer: interinstitutional differences in a multicenter study in Japan. J Surg Oncol 1995; 60: 59-64. |
127) | Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-64. |
128) | Nakajima T, Nashimoto A, Kitamura M, et al: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-7. |
129) | Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000; 11: 837-43. |
130) | Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30. |
131) | Nashimoto A, Nakajima T, Furukawa H, et al: Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-7. |
132) | Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. |
133) | Nakajima T, Kinoshita T, Nashimoto A, et al: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94: 1468-76. |
134) | Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20. |
135) | “GASTRIC(Global Advanced/Adjuvant Stomach Tumor Research International Collaboration)Group”: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-37. |